Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2Prabha Shrestha(National Cancer Institute), Robert Yarchoan(National Cancer Institute)PLoS PathogensJanuary 7, 202110.1371/journal.ppat.1009091Cited by 39SaveCiteExport RISWatch citationsRelated PapersMechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas|Scientific Reports|2023|4